Abstract:Choosing antithrombotic therapy for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) is challenging. Oral anticoagulation is indicated to prevent stroke and systemic embolism in patients with atrial fibrillation but has not been shown to prevent stent thrombosis and is generally not indicated for secondary prevention after acute coronary syndrome. 1-3 Dual antiplatelet therapy is proven to reduce the incidence of recurrent ischemic events and stent thrombosis but is less effective in reducing the incidence of cardioembolic stroke associated with atrial fibrillation. 2-4 The combination of antithrombotic agents, particularly triple therapy with oral anticoagulation and dual antiplatelet therapy, increases the risk of bleeding. 5-7 Thus, an oral antithrombotic regimen with an acceptable benefit–risk profile would be useful in the treatment of patients with atrial fibrillation and concomitant acute coronary syndrome or PCI. Regimens including non–vitamin K antagonist oral anticoagulants appear to offer a number of advantages over vitamin K antagonists, including the potential for less bleeding. 8 Two trials evaluated standard or reduced doses of oral anticoagulants (of dabigatran and rivaroxaban, respectively) in patients with atrial fibrillation who were undergoing PCI, and both trials showed a lower incidence of bleeding with new oral anticoagulant regimens without aspirin than with vitamin K antagonist regimens that included aspirin. 9,10 Neither trial was designed to assess whether the lower incidence of bleeding was due to the use of the standard or reduced doses of the new oral anticoagulants or to the removal of aspirin therapy. We conducted the AUGUSTUS trial (a two-by-two factorial, randomized, controlled clinical trial) to assess the safety and efficacy of standard-dose apixaban as compared with a vitamin K antagonist and of low-dose aspirin as compared with placebo, on a background of concomitant P2Y 12 inhibitor therapy for 6 months in patients with atrial fibrillation and recent acute coronary syndrome or PCI. The trial was designed and led by an academic steering committee whose members were responsible for the conduct of the trial. The Duke Clinical Research Institute (DCRI, Durham, NC) was the academic coordinating center. The trial was sponsored by Bristol-Myers Squibb and Pfizer. The trial protocol (available with the full text of this article at NEJM.org) and all subsequent amendments were approved by national regulatory agencies in participating countries and by institutional review boards or ethics committees at participating sites. An independent data and safety monitoring board reviewed unblinded patient-level data at regular intervals during the trial. Although Bristol-Myers Squibb assisted with data management, all the statistical analyses were performed independently at the DCRI. The initial draft of the manuscript was written by the first author and revised on the basis of comments from the other authors. All the authors vouch for the adherence of the trial to the protocol, and the first, second, and last authors vouch for the accuracy and completeness of the data and analysis. No one who is not an author contributed to writing the manuscript. The committee members and participating investigators are listed in the Supplementary Appendix , available at NEJM.org. The trial rationale and design have been published previously. 11 In brief, AUGUSTUS was a prospective, multicenter, two-by-two factorial, randomized clinical trial comparing apixaban with a vitamin K antagonist and comparing aspirin with placebo in patients with atrial fibrillation who had a recent acute coronary syndrome or underwent PCI (or both). Patients who met all the following criteria were eligible for inclusion: an age of at least 18 years; previous, persistent, permanent, or paroxysmal atrial fibrillation and planned long-term use of an oral anticoagulant; recent acute coronary syndrome or PCI; and planned use of a P2Y 12 inhibitor for at least 6 months. Patients who were using anticoagulation for other conditions (e.g., prosthetic valves, venous thromboembolism, and mitral stenosis) were not eligible. Other key exclusion criteria were severe renal insufficiency, a history of intracranial hemorrhage, recent or planned coronary-artery bypass graft surgery, coagulopathy or ongoing bleeding, and contraindication to a vitamin K antagonist, apixaban, all P2Y 12 inhibitors, or aspirin. All the patients provided written informed consent before -Abstract Truncated-

Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48hours

Perioperative Management of Vitamin K Antagonists and Direct Oral Anticoagulants: A Systematic Review and Meta-analysis

Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation

Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding

Clinical Course and Management of Patients with Emergency Surgery Treated with Direct Oral Anticoagulants or Vitamin K Antagonists—Results of the German Prospective RADOA-Registry

[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine]

Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage

Practical Suggestions for an Optimal Management of Vitamin K Antagonists: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper

European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation

Effectiveness of a self-management program for anticoagulated patients to improve their knowledge about treatment and time in therapeutic range

Non-vitamin K oral anticoagulants as first-line regimen for acute ischemic stroke with non-valvular atrial fibrillation

The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary

Intracerebral haemorrhage in patients taking different types of oral anticoagulants: a pooled individual patient data analysis from two national stroke registries

Comparative analysis of vitamin K antagonists and direct oral anticoagulants for left ventricular thrombus management: a retrospective study utilising TriNetX

When Direct Oral Anticoagulants Should Not Be Standard Treatment

Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios

Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation

Management of urgent invasive procedures in patients treated with direct oral anticoagulants: An observational registry analysis

From the INVICTUS Trial to Current Considerations: It's Not Time to Retire Vitamin K Inhibitors Yet!